Droroloxifene , a new antiestrogen in advanced breast cancer, double blind dose finding study (1991)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- Assunto: ONCOLOGIA
- Language: Inglês
- Source:
- Título: European Journal of Cancer
- Volume/Número/Paginação/Ano: v.27, n.2 supl., p.s55, 1991
- Conference titles: European Conference on Clinical Oncology and Cancer Nursing
-
ABNT
CHEVALLIER, B et al. Droroloxifene , a new antiestrogen in advanced breast cancer, double blind dose finding study. European Journal of Cancer. [S.l.]: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 17 jul. 2025. , 1991 -
APA
Chevallier, B., Brown, C., Bruning, P. F., Deschenes, L., Hegg, R., Malzyner, A., et al. (1991). Droroloxifene , a new antiestrogen in advanced breast cancer, double blind dose finding study. European Journal of Cancer. Faculdade de Medicina, Universidade de São Paulo. -
NLM
Chevallier B, Brown C, Bruning PF, Deschenes L, Hegg R, Malzyner A, Marschner N, Paterson A, Prichard KI, Serin D, Spielmann M. Droroloxifene , a new antiestrogen in advanced breast cancer, double blind dose finding study. European Journal of Cancer. 1991 ;27( 2 supl.): s55.[citado 2025 jul. 17 ] -
Vancouver
Chevallier B, Brown C, Bruning PF, Deschenes L, Hegg R, Malzyner A, Marschner N, Paterson A, Prichard KI, Serin D, Spielmann M. Droroloxifene , a new antiestrogen in advanced breast cancer, double blind dose finding study. European Journal of Cancer. 1991 ;27( 2 supl.): s55.[citado 2025 jul. 17 ] - Superexpressao do oncogene her-2/neu em carcinomas de mama: analise clinica e imunohistoquimica
- Importancia do antigeno carcinoembrionico no prognostico do carcinoma de mama: analise clinica e imuno-histoquimica
- Phase ii trial of navelbine (nvb) in advanced breast cancer (abc)
- Câncer da mama: quadro clínico, diagnóstico e estadiamento
- Tratamento da endometriose com analogos do gnrh
- Propedeutica basica em ginecologia
- Alterações funcionais benignas da mama
- Tratamento neoadjuvante no câncer de mama
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
